CTOs on the Move

Point Biopharma

www.pointbiopharma.com

 
POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Point Biopharma raised $165M on 07/01/2021

Similar Companies

CAMP4 Therapeutics

What if we told you that our bodies make use of only a few hundred different signaling pathways to control all of our 20,000 or so genes. We call it the gene circuitry code, unique for every gene in our body. CAMP4 has built a proprietary 4-D Gene Circuity Platform to codify the discrete set of combinatorial rules used by any human cell type central to disease pathology. By applying the power of computational biology and machine learning algorithms, CAMP4 is able to rapidly solve for druggable targets to control the output of any disease gene of interest.

Hexagon Bio

Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics.

Progressive Medical

Progressive Medical is a Westerville, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Acris Antibodies

Acris Antibodies is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Connect Biopharma

Connect Biopharma (Nasdaq: CNTB) is a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research. With operations and expertise in China, the United States and Australia and clinical development activities in those geographies as well as Europe, Connect Biopharma is building a rich pipeline of internally designed, wholly owned small molecules and antibodies targeting several aspects of T cell biology. Our core expertise is in the use of functional cellular assays with T cells to screen and discover potent drug candidates against immune targets. Our two most advanced clinical-stage programs include highly differentiated product candidates against validated targets.